News & Media Press releases & statements Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Apply filter Year All Years 2023 2022 2021 2020 2019 2018 2017 2016 2015 Category All categories Type - Statement - Press release Topic - Corporate and finance - Global health - Partnerships Research area - COVID-19 - Ebola - RSV - Seasonal influenza Uncategorized Keywords Apply filter Advanced Search Search Search Headlines Only Type All Statement Press release Topic All Corporate and finance Global health Partnerships Research area All COVID-19 Ebola RSV Seasonal influenza From To Asset Types Photos Video Audio Documents Events Standard Aug 22, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Expands Recommendation for Novavax COVID-19 Vaccine, Adjuvanted to Adolescents Aged 12 Through 17 Download Aug 19, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Adolescents Aged 12 Through 17 Download Aug 18, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand for Adolescents Aged 12 Through 17 Download Aug 17, 2022 Novavax' COVID-19 Vaccine Recognized in U.S. Government Delegation Visit to Serum Institute of India Download Aug 17, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Provisional Approval in New Zealand as a First and Second Booster for Adults Download Aug 15, 2022 Novavax Files in Taiwan for Expanded Emergency Use Authorization of Nuvaxovid™ COVID-19 Vaccine in Adolescents Aged 12 Through 17 Download Aug 15, 2022 COVID-19 Novavax Submits Application to the U.S. FDA for Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted as a Booster in Adults Aged 18 and Older Download Aug 12, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Approved in South Korea for Use in Adolescents Aged 12 Through 17 Download Aug 11, 2022 Corporate and finance Novavax to Participate in Fireside Chat at the SVB Securities Virtual Vaccine Forum Download Aug 10, 2022 StatementCOVID-19 Novavax and Serum Institute of India Receive Expanded Emergency Use Authorization for Novavax’ COVID-19 Vaccine in Thailand in Adolescents Aged 12 Through 17 Download Aug 8, 2022 Corporate and finance Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights Download Aug 8, 2022 StatementCorporate and finance Novavax Statement on Second Quarter 2022 Financial Results and Operational Highlights Download Aug 4, 2022 COVID-19 Novavax Announces Initiation of Phase 2b/3 Hummingbird™ Global Clinical Trial for the Novavax COVID-19 Vaccine in Children Aged Six Months Through 11 Years Download Aug 1, 2022 StatementCOVID-19 Novavax Statement on U.S. Vaccinations with the Novavax COVID-19 Vaccine, Adjuvanted Underway Download Aug 1, 2022 Corporate and finance Novavax to Host Conference Call to Discuss Second Quarter 2022 Financial Results and Operational Highlights on August 8, 2022 Download Jul 29, 2022 Novavax Requests Expanded Emergency Use Listing with World Health Organization for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jul 28, 2022 StatementCorporate and finance Novavax CEO Appointed to U.S.-India CEO Forum Download Jul 26, 2022 COVID-19 Novavax Announces Expanded Approval of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 through 17 in Japan Download Jul 26, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Provisional Registration in Australia for Use in Adolescents Aged 12 Through 17 Download Jul 22, 2022 StatementCOVID-19 Novavax Statement on U.S. Availability of the Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 StatementCOVID-19 U.S. Centers for Disease Control and Prevention Endorses Advisory Committee on Immunization Practices’ Recommendation for Novavax COVID-19 Vaccine, Adjuvanted Download Jul 19, 2022 COVID-19 U.S. CDC Advisory Committee Unanimously Recommends Novavax COVID-19 Vaccine, Adjuvanted as a Primary Series for Individuals Aged 18 and Older Download Jul 19, 2022 COVID-19 Novavax Announces Expanded Agreement with SK bioscience to Manufacture COVID-19 Vaccine Containing Omicron Variant and Manufacture the Novavax COVID-19 Vaccine in Prefilled Syringes Download Jul 15, 2022 StatementCOVID-19 Novavax COVID-19 Vaccine to be Reviewed at U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices Meeting on July 19, 2022 Download Jul 14, 2022 StatementCOVID-19 Novavax Statement on European Medicines Agency Nuvaxovid™ Label Update Related to Allergic Reaction Download Jul 13, 2022 COVID-19 U.S. FDA Grants Emergency Use Authorization for Novavax COVID-19 Vaccine, Adjuvanted for Individuals Aged 18 and Over Download Jul 11, 2022 COVID-19 U.S. Government Secures 3.2 Million Doses of Novavax COVID-19 Vaccine Download Jul 7, 2022 StatementGlobal healthCOVID-19 Novavax Files in Switzerland for Expanded Conditional Marketing Authorization of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Individuals Aged 18 and Over Download Jul 7, 2022 StatementGlobal healthCOVID-19 European Medicines Agency Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine Download Jul 5, 2022 COVID-19 Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17 Download Jul 1, 2022 StatementGlobal healthCOVID-19 Novavax Statement on Prototype Vaccine’s Broad Immune Responses and Accelerated Focus on Omicron BA.4/5 as Recommended by the FDA Download Jun 28, 2022 COVID-19 Novavax COVID-19 Data Presented at FDA VRBPAC Meeting Demonstrates Broad Antibody Responses to Both Prototype and Omicron-Specific Variants Download Jun 28, 2022 StatementGlobal healthCOVID-19 Novavax to Participate in Vaccines and Related Biological Products Advisory Committee Review of COVID-19 Vaccines Strain Composition Download Jun 23, 2022 COVID-19 Novavax' Nuvaxovid™ COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan for Use in Individuals Aged 18 and Over Download Jun 23, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Recommended for Expanded Conditional Marketing Authorization in the European Union by CHMP for Adolescents Aged 12 Through 17 Download Jun 23, 2022 StatementGlobal healthCOVID-19 Novavax Files Supplement to a New Drug Submission in Canada for Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 Download Jun 17, 2022 StatementCOVID-19Seasonal influenza Novavax to Showcase Innovative Vaccine Data at Communicable Diseases & Immunisation Conference 2022 Download Jun 13, 2022 COVID-19 Novavax COVID-19 Vaccine Nuvaxovid™ Provisionally Registered in Australia as a Booster in Individuals Aged 18 and Over Download Jun 7, 2022 COVID-19 FDA Advisory Committee Recommends Emergency Use Authorization of Novavax COVID-19 Vaccine for People Aged 18 Years and Older Download Jun 7, 2022 Corporate and financeCOVID-19 Novavax Statement on Stock Trading Halt; FDA Advisory Committee to Review Novavax’ COVID-19 Vaccine Download Jun 3, 2022 StatementCOVID-19 Novavax Statement on US FDA Briefing Document Related to Myocarditis/Pericarditis Download Jun 2, 2022 StatementGlobal healthCOVID-19 Novavax Files in the United Kingdom for Expanded Conditional Marketing Authorization of COVID-19 Vaccination as a Booster in Adults Aged 18 and Over Download May 31, 2022 StatementGlobal healthCOVID-19 Novavax Initiates Phase 3 Trial of its COVID-19 Omicron Strain Vaccine as a Booster Download May 26, 2022 StatementGlobal healthCOVID-19 FDA Confirms Vaccines and Related Biological Products Advisory Committee Review of Novavax’ COVID-19 Vaccine on June 7, 2022 Download May 25, 2022 StatementGlobal healthCOVID-19 Novavax Announces Participation in Oxford University Com-COV3 Booster Trial of COVID-19 Vaccines in Adolescents Aged 12 Through 15 Download May 20, 2022 StatementGlobal healthCOVID-19 Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over Download May 13, 2022 StatementCOVID-19 Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan Download May 9, 2022 Press releaseCorporate and finance Novavax Reports First Quarter 2022 Financial Results and Operational Highlights Download May 6, 2022 StatementCOVID-19 Novavax Submits Variations to Expand Australian and New Zealand Provisional Approval of Nuvaxovid™ COVID-19 Vaccine to Adolescents aged 12 Through 17 Years Download May 6, 2022 StatementCOVID-19 Novavax’ COVID-19 Vaccine Nuvaxovid™ Arrives in Singapore Download Show 5102550100 per page«123456789»